EarningsQ2 2026 Earnings Report
MX:FLGT Q2 2026 EPS Results
Actual EPS-$10.53
Consensus EPS-$8.35
Beat/MissMissed by -$2.18
One Year Ago EPS$1.27
MX:FLGT Q2 2026 Revenue Results
Actual Revenue$1.55B
Expected Revenue$1.71B
Beat/MissMissed by -$156.39M
YoY Revenue Growth+4.38%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeAfter Close
Conference CallThursday, July 30, 2026
MX:FLGT Upcoming Earnings
Fulgent Genetics's next earnings date is estimated for November 6, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:FLGT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed picture: meaningful operational and near-term financial headwinds driven by a complex revenue-cycle transition and loss of volume from a large customer led management to reduce full-year revenue guidance and report wider losses. Offsetting these challenges are strong cash reserves, successful integration of recent acquisitions, sequential margin improvement, continued share repurchases, product and AI advancements, and tangible progress in the therapeutic pipeline (FID-007 and FID-022). The issues are material to near-term results, but the company retains financial flexibility and long-term growth drivers.Company Guidance
Therapeutic Pipeline Progress
FID-007 Phase II completed with encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma; end-of-Phase-II meeting with the FDA scheduled later this summer and Phase III registration trial targeted for H1 2027. FID-022 progressed to Phase I dose escalation with the first dose level completed and maximum tolerated dose expected later this year. Both candidates use Fulgent's proprietary CleanChemo platform (patented and fully owned).
Revenue and Sequential Growth in Q2
Total revenue of $85.4M in Q2 2026, up 4% year-over-year and up 20% sequentially; $16.9M of Q2 revenue attributable to Bako Diagnostics and StrataDX integration.
Anatomic Pathology Strength and Successful Acquisitions
Anatomic Pathology revenue of $37.5M, up 33% year-over-year and 50% sequentially. Bako and StrataDX were integrated with minimal disruption; combined Anatomic Pathology sales team expanded to ~40 (nearly double pre-acquisition). Management estimates ~ $53M contribution from Bako/StrataDX in the second half of the year.
AI and Genomics Product Enhancements
Expanded AI portfolio with a staining-aware Mast AI for accurate mast cell quantification; whole genome sequencing moved to Illumina TruePath with mean coverage increased from ~40x to 60–70x and repeat expansion coverage expanded from 21 to 64 loci. RISE RNA integration and scheduled Epic Aura EMR integration (early adopters Q3) are expected to improve diagnostic capability and clinician access.
Strong Liquidity and Continued Share Repurchases
Ending cash, cash equivalents, restricted cash, and marketable securities of $551.5M. Repurchased >1.5M shares in Q2 and >7.5M shares since program inception with $75.8M remaining authorization. Management projects ending-year cash of approximately $610M under current assumptions.
Sequential Improvement in Operating Margins
GAAP operating margin improved sequentially from -48.7% in Q1 to -42.3% in Q2; non-GAAP operating margin improved from -27.7% to -26.2% sequentially, indicating modest operational progress despite headwinds.
MX:FLGT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed